Shopping Cart
- Remove All
- Your shopping cart is currently empty
GW6471 is an antagonist of PPARα with IC50 of 0.24 μ M. GW6471 enhances the binding affinity of the PPAR α ligand-binding domain to the co-repressor proteins SMRT and NCoR.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $32 | In Stock | |
5 mg | $73 | In Stock | |
10 mg | $107 | In Stock | |
25 mg | $227 | In Stock | |
50 mg | $449 | In Stock | |
100 mg | $656 | In Stock | |
500 mg | $1,360 | In Stock | |
1 mL x 10 mM (in DMSO) | $123 | In Stock |
Description | GW6471 is an antagonist of PPARα with IC50 of 0.24 μ M. GW6471 enhances the binding affinity of the PPAR α ligand-binding domain to the co-repressor proteins SMRT and NCoR. |
In vitro | METHODS: RCC cells Caki-1 (VHL wild type) and 786-O (VHL mutant) were treated with GW6471 (12.5-100 µM) for 72 h. Cell viability was measured using MTT assay. |
In vivo | METHODS: To assay in vivo antitumor activity, GW6471 (20 mg/kg) was injected intraperitoneally every two days for four weeks into Nu/Nu mice bearing the RCC tumor Caki-1. RESULTS: In vivo treatment of xenograft mouse model with PPARα antagonist GW6471 attenuated RCC growth. [2] |
Alias | GW 6471 |
Molecular Weight | 619.67 |
Formula | C35H36F3N3O4 |
Cas No. | 880635-03-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: 16.67 mg/mL (26.9 mM), Sonication is recommended. 10% DMSO+90% Saline: 0.25 mg/mL (0.4 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.